Evoke Pharma (EVOK) announced that U.S. Patent No. 12,377,064 for GIMOTI - metoclopramide, nasal spray, used to treat moderate to severe gastroparesis, has been added to the FDA's Orange Book.
The patent extends until November 17, 2038—eight years beyond the company's previous Orange Book patent expiring in May 2030.
CEO Matt D'Onofrio emphasized that the patent reflects Evoke's dedication to innovation, protecting its investment while ensuring long-term access to effective non-oral treatment options for diabetic gastroparesis patients. The move supports Evoke's strategy to maximize GIMOTI's commercial lifespan.
EVOK currently trades at $6.3 or 8.06% higher on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.